These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38636269)

  • 1. Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders.
    Chen H; Xu Z; Zhou Y; Jiang YH; Chen J; Xiong Y; Zhou M; Wu X; Hong D
    Mult Scler Relat Disord; 2024 Jun; 86():105606. PubMed ID: 38636269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study.
    Gong J; Qiu W; Zeng Q; Liu X; Sun X; Li H; Yang Y; Wu A; Bao J; Wang Y; Shu Y; Hu X; Bellanti JA; Zheng SG; Lu Y; Lu Z
    Mult Scler; 2019 Aug; 25(9):1316-1325. PubMed ID: 30113252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perturbed microbial ecology in neuromyelitis optica spectrum disorder: Evidence from the gut microbiome and fecal metabolome.
    Xie Q; Sun J; Sun M; Wang Q; Wang M
    Mult Scler Relat Disord; 2024 Dec; 92():105936. PubMed ID: 39418776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
    Shi Z; Qiu Y; Wang J; Fang Y; Zhang Y; Chen H; Du Q; Zhao Z; Yan C; Yang M; Zhou H
    J Neuroimmunol; 2020 Feb; 339():577126. PubMed ID: 31841737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Barrier Breakdown and Mucosal Microbiota Disturbance in Neuromyelitis Optical Spectrum Disorders.
    Cui C; Tan S; Tao L; Gong J; Chang Y; Wang Y; Fan P; He D; Ruan Y; Qiu W
    Front Immunol; 2020; 11():2101. PubMed ID: 32983166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of gastrointestinal toxicity in neuromyelitis optica spectrum disorder patients treated with mycophenolate mofetil: insights from a mouse model and human study.
    Li G; Xia L-J; Shu Y-Q; Wan L; Huang Q; Ma X-Y; Zhang H-Y; Zheng Z-J; Wang X-R; Zhou S-Y; Gao A; Ren H; Lian X-L; Xu D; Tang S-Q; Liao X-P; Qiu W; Sun J
    Microbiol Spectr; 2024 Aug; 12(8):e0430723. PubMed ID: 38916339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders.
    Zhang J; Xu YF; Wu L; Li HF; Wu ZY
    Mult Scler Relat Disord; 2020 Sep; 44():102217. PubMed ID: 32534438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
    J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention.
    Cui C; Ruan Y; Qiu W
    J Clin Neurosci; 2020 Dec; 82(Pt B):193-199. PubMed ID: 33257156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GV-971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities.
    Yang X; Zhangyi Z; Yu A; Zhou Q; Xia A; Qiu J; Cai M; Chu X; Li L; Feng Z; Luo Z; Sun G; Zhang J; Geng M; Chen S; Xie Z
    CNS Neurosci Ther; 2024 Jul; 30(7):e14847. PubMed ID: 38973196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
    Ahn SH; Kim SM; Sung JJ
    Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.
    Cheng X; Zhou L; Li Z; Shen S; Zhao Y; Liu C; Zhong X; Chang Y; Kermode AG; Qiu W
    Front Immunol; 2022; 13():827865. PubMed ID: 35126400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.